All In Biotech

Drug Trial Radar · NCT00362856

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.

Last checked: Nov 19, 2026Latest source record: Sep 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Sep 13, 2006

Primary completion

Mar 6, 2007

Study completion Mar 6, 2007

Sponsor

Lead sponsor
9 Meters Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.

Conditions

  • Celiac Disease

Interventions

  • larazotide acetateDrug

    capsule

  • PlaceboDrug

    capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the safety and tolerability of multiple, oral doses of larazotide acetate in celiac disease subjects that maintain a gluten-free diet.Time frame: Safety measurements were performed at Screening and at Day 0, 7, 14, and 21 ('End of Study'). Any change from baseline value was calculated at each subsequent visit until "End of Study" (Day 21).
  2. To evaluate the efficacy of multiple dose levels of larazotide acetate in preventing intestinal permeability changes induced by gluten challengeTime frame: On Days 0, 6, 13, and 20 subjects drank a solution of lactulose and mannitol. Subject's urine was collected during the day on Day 0 and overnight prior to subsequent visits and analyzed for LAMA recoveries via standardized methodologies.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Scottsdale, Arizona

  • Site not named

    San Diego, California

  • Research Site

    Boston, Massachusetts

  • Research Site

    Rochester, Minnesota

  • Site not named

    Morristown, New Jersey

  • Site not named

    Bismarck, North Dakota

  • Research Site

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Research Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.